Tegoprazan

HK inno.N Corp. launched its GERD drug, K-CAB, in six Latin American countries, marking a global expansion milestone. K-CAB, a P-CAB treatment, has shown rapid efficacy and safety, achieving top sales in South Korea. The drug has entered 18 Latin American countries, with significant market penetration in Mexico. Academic conferences have promoted K-CAB, with Dr. David Pura endorsing its use in Helicobacter eradication therapies. HK inno.N aims to promote domestically developed drugs globally.

HK inno.N received SEC recommendation for K-CAB tablets (25 mg and 50 mg) to treat GERD and gastric ulcers in India. The 50 mg tablet is recommended for erosive and non-erosive GERD, while the 25 mg is for maintenance therapy. A local phase 3 trial for H. pylori eradication therapy was suggested. K-CAB, launched in 2019, is now available in 46 countries and generated 160.2 billion won in sales in Korea.

Jaqbo, a new P-CAB by Onconic Therapeutics, debuted in Korea's peptic ulcer market with modest sales of $380k, lagging behind rivals K-CAB and Fexuclue. Despite strategic partnerships and significant investment, Jaqbo faces an established market dominated by K-CAB and Fexuclue, with over 20 companies preparing to launch generic versions of Vicinti.